<DOC>
	<DOC>NCT01362933</DOC>
	<brief_summary>Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.</brief_summary>
	<brief_title>National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT) Patient already included in a trial studying antithrombotic therapy Patient refusing the study Patient under 18 and/or not competent to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>PE</keyword>
	<keyword>DVT</keyword>
	<keyword>SVT</keyword>
	<keyword>LMWH</keyword>
	<keyword>VKA</keyword>
	<keyword>international Venous Thromboembolism Recommendations</keyword>
</DOC>